GALECTO BIOTECH ApS: Financial statements 2019
CVR: 34878366
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
GALECTO BIOTECH ApS (CVR 34878366) has filed annual accounts for 2019. In 2019, the company reported a gross profit of EUR 2,423,114 and a net result of EUR 323,877 compared with EUR -3,659,814 the year before. Equity in the 2019 report amounted to EUR 2,690,360. The solvency ratio was 65.9%. The company had 11 employees in the financial year.
- Gross Profit
- EUR 2,423,114
- Profit/Loss
- EUR 323,877
- Equity
- EUR 2,690,360
- Total Assets
- EUR 4,084,968
- Employees
- 11
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 2.4 mio. EUR | 324 t. EUR | 2.7 mio. EUR | 11 |
| 2018 | - | -2.6 mio. EUR | -3.7 mio. EUR | -12.8 mio. EUR | 5 |
| 2017 | - | -2.1 mio. EUR | -2.7 mio. EUR | -9.2 mio. EUR | 4 |
| 2016 | - | -1.3 mio. EUR | -1.8 mio. EUR | -6.5 mio. EUR | - |
| 2015 | - | 865 t. EUR | -504 t. EUR | -4.6 mio. EUR | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of May 15, 2019, EY Godkendt Revisionspartnerselskab has been appointed auditor of GALECTO BIOTECH ApS.
As of May 15, 2019, BAKER TILLY DENMARK GODKENDT REVISIONSAKTIESELSKAB has stepped down as auditor of GALECTO BIOTECH ApS.
GALECTO BIOTECH ApS has published its annual report for 2018. Gross profit came to DKK -2,569,142, and the net result was DKK -3,659,814.
About GALECTO BIOTECH ApS
GALECTO BIOTECH ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Garrett Michael Winslow. The company is owned by Galecto Biotech AB. The company has 3 employees (2018). In 2025, the company reported a gross profit of EUR 1,039,275 and a net result of EUR -709,079 compared with EUR 310,297 the year before. Equity in the 2025 report amounted to EUR 7,844,625.